Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.

Cancer chemotherapy and pharmacology - 1 Jan 2001

Dowlati A, Levitan N, Gordon N H, Hoppel C L, Gosky D M, Remick S C, Ingalls S T, Berger S J, Berger N A

Abstract excerpt

PURPOSE: In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this h...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Etoposide

Share to Hypoxanthine Phosphoribosyltransferase

Share to Lung Neoplasms

Share to Topoisomerase I Inhibitors

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 11269740
DOI: 10.1007/s002800000211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11269740-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.PMID 11269740Read ↗

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Semantic proximity Read ↗

Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.Semantic proximity Read ↗

Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell LinesSemantic proximity Read ↗

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).Semantic proximity Read ↗

Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroSemantic proximity Read ↗

Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.Semantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.Semantic proximity Read ↗

Relationship Between Topotecan Systemic Exposure and Tumor Response in Human Neuroblastoma XenograftsSemantic proximity Read ↗

Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.Semantic proximity Read ↗

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.Semantic proximity Read ↗

[131I]<i>meta</i>-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline TransporterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.